1. Scrip
  2. >>R&D

Dyne Reports Progress Building Next-Generation Exon Skipping Franchise In DMD

 
• By Jessica Merrill

The company reported updated data from the Phase I/II DELIVER trial testing DYNE-251 in patients with Duchenne muscular dystrophy (DMD) and announced leadership changes.

efficacy
Dyne's DMD drug continues to show efficacy in Phase I/II • Source: Shutterstock

The drug development focus in Duchenne muscular dystrophy (DMD) has been on gene therapy recently, but Dyne Therapeutics is working to develop next-generation exon-skipping medications that would compete with Sarepta Therapeutics, Inc.’s established exon-skipping franchise, including Exondys 51 (eteplirsen).

Key Takeaways
  • Updated data from a Phase I/II clinical trial DELIVER testing DYNE-251 in patients with DMD demonstrated greater dystrophin expression than what was seen in clinical trials for Sarepta’s Exondys 51.

The company announced updated data on 3 September from the ongoing Phase I/II DELIVER trial testing DYNE-251 in patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.